Recent News for EFTR - eFFECTOR Therapeutics, Inc.

Date	Title
Jun 24	eFFECTOR Therapeutics to wind down operations, expects to be delisted from Nasdaq
Jun 24	eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
May 20	eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer